Refractive errors in children: analysis among preschool and school children in Tuzla city, Bosnia and Herzegovina.

Aim To establish the prevalence of refractive errors in preschool and school children between 4 and 15 years of age, living in Tuzla, Bosnia and Herzegovina. Methods Children from all elementary schools in the city of Tuzla and as well from eight day-care centres were screened for refractive errors in the period 2015-2019. Any child, who failed to pass the screening examination, was referred to an ophthalmologist for complete ophthalmological evaluation. The obtained data were analysed using non-parametric statistics. Results The highest number of children who were tested after the screening process was during 2015. A total of 7415 children (3790 males and 3625 females), in the age range of 4-15 were screened. In the total sample of children who were completely evaluated (n=145; 290 eyes) the most common refractive error was astigmatism, in 152 (52.4%) eyes. In the preschool children (n=18; 36 eyes), the most common refractive error was astigmatism, in 19 (52.8%) eyes, followed by hyperopia, in 9 (25%) eyes. In the school children (n=127) (254 eyes), the most common refractive error was astigmatism, in 133 (52.4%) eyes, followed by myopia, in 92 (36.2%) eyes. The overall prevalence of refractive errors was 1.95% (145 with refractive error out of 7415 screened). Conclusion Prevalence of refractive errors is high enough to justify a school eye screening programme.

Is Prevention of Glaucoma Possible in Bosnia and Herzegovina?

INTRODUCTION: Glaucoma is the second leading cause of blindness in the world and represents a significant social and health problem. Early detection of glaucoma enables early initiation of treatment and may delay disease progression. The aim of this work is to determine whether it is possible to detect glaucoma in early stages. METHODS: A public awareness campaign was carried out in University Clinic Center (UCC) in Tuzla, Bosnia and Herzegovina (B&H) during 2012, 2013, 2014 and 2015 Glaucoma Week, with one-day, free of charge screening of individuals. This screening program was composed of getting brief medical history, slit-lamp examination including intraocular pressure and anterior chamber dept evaluation and non-mydriatic fundus exam with evaluation of the cup/disk ration. RESULTS: A total of 682 individuals were screened, 277 were male and 405 were female. The youngest individual was 8 years old and the oldest individual was 84 years old. The mean age was 57.6 years. Intraocular pressure higher then 21,9 mmHg was found in 83 patients. CONCLUSION: Glaucoma is a disease that affects visual acuity and gradually leads to blindness. It occurs in all age groups in both sexes and in all races. Early detection of disease and proper treatment can prevent permanent loss of vision. Detection and early treatment of glaucoma must become one of the leading public health programs in B&H.

Incidence of endophthalmitis after intravitreal application of anti VEGF therapy at the University Clinical Center in Tuzla, Bosnia and Herzegovina.

AIM: To report the incidence of endophthalmitis following the use of intravitreal injection of anti- vascular endothelial growth factor (anti VEGF) therapy. METHODS: In this retrospective study a total of 986 intravitreal bevacizumab injections were applied between January 2008 and April 2015 at the University Clinical Center Tuzla, Bosnia and Herzegovina (BiH). Since January 2012, a total of 55 intravitreal ranibizumab injections were applied and since October 2014, 60 intravitreal aflibercept injections were applied to patients. RESULTS: Two cases of endophthalmitis following intravitreal injection of bevaciuzumab occurred and none after ranibizumab or aflibercept. The overall incidence of clinical endophtahlmitis was 0.2%. CONCLUSION: The results suggest that a low rate of endophthalmitis can be achieved by means of a protocol. This is a very important study as it is the first of this kind in BiH that documents the incidence of endophthalmitis after intravitreal application. Currently, bevacizumab in BiH is most frequently used intravitreal anti-vascular endothelial growth factor due to very low price.